MAPK14 and neuroblastoma: In neuroblastoma cells, Sirt2-SUMOylation controls the level of p38 acetylation and avoids p38-mTORC2-AKT overactivation, and SUMOylation-deficient Sirt2 loses its ability to inhibit tumor processes 134.